Better Therapeutics (BTTX) Short Interest Ratio & Short Volume

Short interest is the volume of Better Therapeutics shares that have been sold short but have not yet been closed out or covered. As of March 15th, traders have sold 2,560,000 shares of BTTX short. 8.29% of Better Therapeutics' shares are currently sold short. Learn More on Better Therapeutics' current short interest.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Better Therapeutics: Concourse Financial Group Securities Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 8.29% of Better Therapeutics' floating shares are currently sold short.

Better Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 2,560,000 shares, an increase of 20.2% from the previous total of 2,130,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Better Therapeutics currently has issued a total of 49,860,000 shares. Some of Better Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Better Therapeutics currently has a public float of 30,890,000 shares.

8.29% of Better Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Better Therapeutics: Motus GI Holdings, Inc. (0.46%), Sintx Technologies, Inc. (5.38%), Allarity Therapeutics, Inc. (9.18%), Invitae Co. (26.15%), Aditxt, Inc. (0.99%), Aptevo Therapeutics Inc. (5.13%), Smart for Life, Inc. (15.01%), China SXT Pharmaceuticals, Inc. (4.78%), Acorda Therapeutics, Inc. (0.66%), Evelo Biosciences, Inc. (2.11%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Cummins Inc. ($8.93 billion), Canadian Natural Resources Limited ($7.79 billion), Super Micro Computer, Inc. ($4.31 billion), T-Mobile US, Inc. ($4.00 billion), General Motors ($3.36 billion), Occidental Petroleum Co. ($3.10 billion), Charter Communications, Inc. ($2.92 billion), Coinbase Global, Inc. ($2.74 billion), Tractor Supply ($2.72 billion), and Moderna, Inc. ($2.31 billion). View all of the most shorted stocks.

Short selling BTTX is an investing strategy that aims to generate trading profit from Better Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Better Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of BTTX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BTTX, twice per month. The most recent reporting period available is March, 15 2024.